FTREFortrea Holdings Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−6% a year). Little growth is priced in even as revenue fell 0% a year over three years, potential value, or a value trap.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What FTRE's price assumes
Today's price asks for −5.8% free cash flow growth a year; over the last three years Fortrea Holdings Inc. delivered 0.81%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 12%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- −5.8%
Growth the price implies · The price pays for −5.8% free cash flow growth a year for a decade; the business has delivered +0.81% a year over the last three.
- Price / book
- 3.20
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 3.20
- EV / EBIToperating margin −0.40%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.96
- Free cash flow, trailing twelve months
- $196M
- Market capitalisation
- $1.68B
- 3-year revenue growth
- −0.09%
- 3-year free cash flow growth
- +0.81%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.